-
Idecabtagene vicleucel, sold
under the
brand name
Abecma, is a cell-based gene
therapy to
treat multiple myeloma. The most
common side
effects include...
- (2016),
Kymriah (2017),
Luxturna (2017),
Onpattro (2018),
Zolgensma (2019),
Abecma (2021), Adstiladrin,
Roctavian and
Hemgenix (all 2022). Most of
these approaches...
- (York Pharma)
Abbokinase ABC Pack ABCD
abciximab (INN)
abecarnil (INN)
Abecma abediterol (INN)
Abegrin Abelcet (Sigma-Tau), also
known as amphotericin...
-
Evaluation and
Research (2021-03-27). "
ABECMA (idecabtagene vicleucel)". FDA.
European Medicines Agency (2023-07-27). "
Abecma". EMA.
Center for
Biologics Evaluation...
-
treatment for head and neck
squamous cell
carcinoma Idecabtagene vicleucel (
Abecma):
treatment for
multiple myeloma Lovotibeglogene autotemcel (Lyfgenia):...
-
medical use in the
United States in
September 2023.
Idecabtagene vicleucel (
Abecma) –
first cell-based gene
therapy was
approved by FDA in 2021 for the treatment...
- (triamcinolone acetonide) Kenalog-40 (triamcinolone acetonide)
Oncology Abecma (idecabtagene vicleucel)
BiCNU (carmustine)
Breyanzi (lisocabtagene maraleucel)...
- The U.S. Food and Drug
Administration (FDA)
approves Abecma to
treat multiple myeloma.
Abecma is the
first cell-based gene
therapy approved by the FDA...
-
Breyanzi (lisocabtagene maraleucel),
Carvykti (ciltacabtagene autoleucel),
Abecma (idecabtagene vicleucel), and
Kymriah (tisagenlecleucel). "Hackensack Meridian...
- maraleucel)". FDA. Research,
Center for
Biologics Evaluation and (2021-04-21). "
ABECMA (idecabtagene vicleucel)". FDA. Research,
Center for
Biologics Evaluation...
